They decided to receive AstraZeneca’s corona vaccine …

Input 2020.12.04 15:16

Laggards to Pfizer and Moder … Expected to complete Phase 3 clinical trial later this year
The immunity claim for the manufacturer’s vaccine side effects and the controversy over the safety of efficacy are still to blame

It is reported that the government has completed a Phase 3 clinical trial such as Pfizer, Bioentech and Modena, and has signed a vaccine supply contract with AstraZeneca, a laggard rather than a leader who is at the forefront of Corona 19 vaccine distribution. AstraZeneca’s COVID-19 vaccine is a fallacy in the clinical process, leading to controversy over its reliability and further clinical studies are needed. The Korean government has announced multiple times that it will prioritize safety and efficacy in securing the Corona 19 vaccine.

It is known that the government will announce the current status of the entire Corona 19 vaccine contract and the amount of protected assets around next week. AstraZenekawa was reported to have signed a vaccine supply contract late last month, but a government official said: “We cannot disclose in terms of negotiation strategy because negotiations are ongoing with various companies.”

AstraZeneca’s COVID-19 vaccine has not yet come out with final results for phase 3 clinical trials. In November, an analysis of interim data on corona 19 vaccine revealed that the average immune effect was 70%, but it is known that there has been a mistake on the part of the researchers and the controversy over reliability has increased. AstraZeneca, which originally called the mistake “luck,” announced it would eventually proceed with further clinical trials. We aim for completion by this year. Assuming a positive result will come out, vaccination will be possible around next spring if you follow procedures such as applying for approval to use the vaccine from the Korean Ministry of Food and Drug Safety.

On the other hand, Pfizer’s Corona 19 vaccine is already approved for emergency use in the UK, and the US is also about to get approval from the Food and Drug Administration (FDA). Modena is also facing approval from the British and US authorities. The COVID-19 vaccine from the two companies showed a prevention effect of more than 90% as a result of the final Phase 3 clinical trial.

AstraZeneca’s COVID-19 vaccine controversy continues, but the government hasn’t officially disclosed which vaccine the company will be introducing and how much, other than the fact that it is negotiating with global pharmaceutical companies. If specific trading conditions are disclosed, it is difficult to strategically disclose other trading.

There are also observations that negotiations are delayed due to requests for exemption from vaccine side effects by pharmaceutical companies. Lee Sang-won, director of epidemiological investigation and analysis at Central Defense Countermeasures Headquarters, also said during the regular briefing for Corona 19 on the 3, “I know that the request for exemption from (vaccine manufacturers) is common. to all countries as well as to Korea “.

It takes about 10 years to develop a vaccine and verify its safety and efficacy. However, in the midst of the corona pandemic (infectious disease pandemic), global pharmaceutical companies have shortened this period to about a year, raising concerns about the vaccine. In the United States and Europe, the state makes direct damages from vaccination or, if the victim wins against the pharmaceutical company, the government has prepared measures to compensate for it. The same goes for Japan.

When introducing the Corona 19 vaccine, it is very likely that the elderly will be the top priority for vaccination. The United Kingdom, which has approved the Pfizer Corona 19 vaccine for the first time in the world, intends to give priority to the elderly. Director Lee Sang-won also said, “It is a common feature of all countries to put medical personnel and the vaccination-vulnerable class at the forefront of responding to infectious diseases,” he said. “I think Korea will fully reflect this policy.”

However, among the interim results of AstraZeneca’s COVID-19 vaccine phase 3 clinical trials, all participants who received half the dose in the first dose were found to be under the age of 55 and had no elderly population. Earlier, Kwon Jun-wook, head of the second vice president of Bang Dae-bon, commented on Pfizer’s clinical results in the United States on the 11th of last month. I have described it. At the time, Pfizer revealed that the preventive effect of the Corona 19 vaccine was 90%, but the government was cautious.

The AstraZeneca vaccine is commissioned by SK Bioscience and the price per dose is $ 4, less than Pfizer’s $ 19.5 and Modena’s maximum of $ 27. .

The timing of the Corona 19 home vaccination has been brought forward from the first half to the second quarter. In a briefing on the 11th of last month, Kwon Joon-wook, head of the second vice president of Bang Dae-bon, said, “We will aim for home vaccination in the second half of next year” in a briefing. 19) We can start vaccination “.

As the government presented the vaccine purchase contract, it was reported that it will provide compensation for side effects and specific distribution plans, such as priority targeting.